CPA PHARMA NEWS!!! BioAlliance Pharma receives US & Japanese patent for Oravig and Sitavig BioAlliance Pharma SA, an innovative company dedicated to the development of orphan oncology products and supportive care products, has received two key patents from the American and Japanese Offices for protecting two of its products; Oravig (miconazole for the treatment of oropharyngeal candidiasis) and Sitavig (acyclovir for the treatment of labial herpes). With these two new patents, BioAlliance Pharma’s patent portfolio consists of 19 families of published patents, including 285 patents and patent applications for technologies or innovative products. More than 70 per cent of the portfolio is composed of patents providing long-term protection for the products. “The industrial property is a key asset for BioAlliance and lies at the core of the Company’s growth strategy. The reinforcement and the territory expansion of our patents allow to ensure the largest and longest possible protection, optimizing our programs’ value. One such example is the grant of these two new patents”, declared Judith Greciet, CEO of BioAlliance Pharma. In addition to the first Japanese patent protecting the mucoadhesive tablet, and further to the patent protections obtained for Europe, the US and China, this grant is the first one specific to Sitavig in Japan for the treatment of labial herpes. The American patent office announced its decision to deliver a new grant covering Oravig, a miconazole mucoadhesive tablet for the treatment of oropharyngeal candidiasis. This new patent enables BioAlliance to expand the scope of protection already given by two US patents protecting Oravig until 2022. “These two patent grants strengthen and extend the protection for both Oravig and Sitavig in the US and Japan respectively while stressing out the innovative nature of the Lauriad mucoadhesive tablet formulation. Oravig’s patent reinforces and ensures its protection for about ten more years on the US territory while coinciding with the commercial product launch initiated by Vestiq,” stated Aude Michel, Head of Corporate Business Development of BioAlliance Pharma. “The protection obtained for Sitavig until 2027 on the Japanese territory should reinforce its attractiveness in our search for commercial partners on an international level.” BioAlliance Pharma is dedicated to cancer and supportive care treatment with a focus on resistance targeting and orphan products, the company also conceives and develops innovative products, for specialty markets especially in the hospital setting and for orphan or rare diseases Source: Pharmabiz
Posted on: Mon, 15 Jul 2013 14:30:00 +0000